CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

By N. Mattsson, Henrik Zetterberg, Oskar Hansson, N. Andreasen, L. Parnetti, Michael A G Jonsson, S. Herukka, W. M. van der Flier, M. Blankenstein, Michael Ewers and 19 more. Journal of the American Medical Association (JAMA), 2009

1,205 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Multimodal Classification of Alzheimer’s Disease and Mild Cognitive Impairment (2011, background): “, 2001), and quantification of specific proteins measured through CSF (Bouwman et al., 2007b; Fjell et al., 2010; Mattsson et al., 2009; Shaw et al., 2009).”
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis (2014, methodology): “(%) 103 (60)/69 (40) 55 (64)/31 (36) 36 (71)/15 (29) 12 (34)/23 (66) 0.”
Mild cognitive impairment: ten years later. (2009, result): “ing a large group of participants with MCI essentially replicated the findings from Hansson et al.(44) A similar study from the ADNI recently reported the utility of CSF biomarkers in predicting progression, so there is a wealth of data now converging that CSF may provide useful information in predi”